PATENT CLAIM ANALYSIS

Application Number: 15760170
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "450000"]

Abstract:
Lipid nanoparticles and methods of making and using the same, including pharmaceutical compositions and kits, and the targeted delivery of drugs in various treatment methods. The nanoparticle formulation includes phospholipids, triglycerides, cholesterol, cholesteryl ester, apolipoprotein E3 (ApoE3), and a lipophilic therapeutic agent.

Claim (Index 30):
A method of manufacturing the lipid nanoparticles according to  claim 1 , comprising:\n preparing an organic phase comprising the phospholipid, triglyceride, cholesterol ester, and free cholesterol components and the therapeutic agent; preparing an aqueous phase comprising water, Poloxamer 188, sodium taurodeoxicolate, sodium taurocolate and choline chloride; injecting the organic phase into the aqueous phase through an injection nozzle in a highly turbulent regime to obtain the lipid nanoparticles; concentrating the lipid nanoparticles to the appropriate concentration of total lipids; and adding ApoE3 in aqueous solution to the obtained nanoparticles.

Metadata:
- Claim Count in Document: 66.0
- Percentile: 90.0
- Lexical Diversity: 1.35897
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10724833', '11648808', '11802197', '11513756', '11802727']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7182098778048102
- 35 USC 102 Novelty (BERT): 0.5205792544221807
- Combined Prediction Score: 0.6984468154665473
- Mean Citation Score: 279.559728
- Max Citation Score: 291.0936
- Similarity Product: 189.1127158091068

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test